Novel sp3-rich amine and heterocyclic compounds for antimycobacterial drug discovery
Synthetic chemistry capability delivering novel amines, benzylamines, carboxylic acids, and sp3-rich cyclohexyl intermediates via C–H activation for tuberculosis drug discovery. Supports SAR exploration of heterocycles and pendant amines targeting mycobacterial pathways.
Overview
This offering provides access to a synthetic chemistry pipeline focused on novel amine, benzylamine, and carboxylic acid intermediates designed for antimycobacterial drug discovery. The work centers on inhibiting mycobacterial targets through structure–activity relationship (SAR) exploration of heterocycles and pendant amines. A distinguishing capability is the production of sp3-rich cyclohexyl-bearing compounds accessed through C–H activation chemistry, which represents a new direction beyond conventional flat-molecule synthesis.
Technical specifications
Core synthetic capabilities:
- Preparation of novel amines from nitro precursors
- Synthesis of benzylamines from nitrile starting materials
- Generation of carboxylic acids from ester precursors
- C–H activation routes to sp3-rich cyclohexyl intermediates
- Flexible analog generation to support systematic SAR studies
Compound features:
- Emphasis on three-dimensional, sp3-rich scaffolds to expand chemical diversity beyond flat aromatic systems
- Heterocyclic cores paired with pendant amine functionality tailored to mycobacterial target engagement
Technology readiness level
The amine, benzylamine, and carboxylic acid syntheses represent established, routinely practiced routes enabling rapid analog preparation. The C–H activation chemistry yielding sp3-rich cyclohexyl compounds is newly initiated and at an early exploratory stage, offering a novel but emerging direction for collaborative development and validation.
About Montana State University
Montana State University's substantial research enterprise growth has been accompanied by focused investments in innovation and research translation, creating new opportunities for companies to engage with MSU research and expertise. A particular strength is MSU’s network of specialized centers, institutes, and industry-accessible core facilities, which bring together multidisciplinary expertise, advanced research infrastructure, testing capabilities, and established pathways for working with industry partners. MSU is one of a select group of universities participating in the NSF's Accelerating Research Translation (ART) program, which is building the capacity and infrastructure needed to translate more research discoveries into solutions with real-world impact. The growing MSU Innovation Campus and expanding incubator infrastructure provide additional opportunities for university-industry interaction, startup development, and technology-focused companies. These efforts are complemented by MSU’s Technology Transfer Office, which works with researchers and companies to protect and license MSU inventions and facilitate industry-sponsored research collaborations.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.